IBD Management: Vedolizumab, Ustekinumab, and JAK Inhibitors in UC and Crohn Disease
Vedolizumab: Gut-Selective Integrin Blockade
Vedolizumab, an anti-α4β7 integrin antibody, provides gut-selective immunosuppression without systemic immune compromise. In the GEMINI 1 trial (UC), vedolizumab achieved clinical remission in 42% versus 16% placebo at week 52. In GEMINI 2 (Crohn disease), remission rates were more modest at 39% versus 22% for placebo. The VARSITY trial directly compared vedolizumab to adalimumab in UC, demonstrating vedolizumab superiority for clinical remission at week 52 (31% vs 23%, p=0.006) and mucosal healing (40% vs 28%).
Vedolizumab is generally positioned as first-line biologic in moderate-to-severe UC given the VARSITY data and its favorable safety profile. In Crohn disease, it is most effective in TNF-naive patients and may have slower onset than TNF inhibitors, making it less ideal for patients requiring rapid disease control.
Ustekinumab: IL-12/23 Blockade
Ustekinumab targets the p40 subunit shared by IL-12 and IL-23. The UNITI trials demonstrated clinical response in 56% of TNF-failure Crohn patients at week 6 with IV induction (6 mg/kg). Maintenance with 90 mg SC every 8 weeks achieved clinical remission in 54% at week 44. In UC, the UNIFI trial showed 44% remission at week 44 with q8w dosing. Ustekinumab offers particular utility in patients with concomitant psoriasis or psoriatic arthritis, and in TNF-experienced Crohn disease patients where it has demonstrated consistent efficacy.
JAK Inhibitors: Tofacitinib and Upadacitinib
Tofacitinib (10 mg BID induction, 5-10 mg BID maintenance) was the first oral small molecule approved for UC, achieving remission in 41% versus 11% placebo at week 52 in OCTAVE Sustain. Upadacitinib, a more selective JAK1 inhibitor, demonstrated superior efficacy in the U-ACHIEVE and U-ACCOMPLISH trials (UC induction remission 26-34% vs 4-5% placebo at week 8) and is also approved for Crohn disease based on the U-EXCEL and U-EXCEED trials (clinical remission 50-52% vs 29% placebo at week 52).
Sponsored
JAK Inhibitor Safety: Navigating the ORAL Surveillance Signal
The ORAL Surveillance trial in rheumatoid arthritis showed increased rates of MACE and malignancy with tofacitinib versus TNF inhibitors in patients over 50 with cardiovascular risk factors. The FDA subsequently added boxed warnings to all JAK inhibitors. In IBD-specific data, the absolute cardiovascular and malignancy risk appears lower given the younger patient population, but current guidelines recommend JAK inhibitors after failure of at least one biologic in patients over 65 or those with cardiovascular risk factors. VTE risk is dose-dependent and requires clinical vigilance.
Treatment Sequencing: A Practical Approach
For moderate-to-severe UC in biologic-naive patients, vedolizumab or infliximab represent reasonable first-line options. In Crohn disease, anti-TNF agents (infliximab, adalimumab) or ustekinumab are preferred first-line depending on disease phenotype. Perianal Crohn disease favors infliximab based on ACCENT II data. After first biologic failure, mechanism switching (rather than within-class cycling) is supported by higher response rates: TNF failure patients respond better to vedolizumab, ustekinumab, or JAK inhibitors than to a second TNF agent. Combination therapy with an immunomodulator (azathioprine or methotrexate) improves infliximab and adalimumab efficacy but is not established for vedolizumab, ustekinumab, or JAK inhibitors.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.